Skip to main content
Contact +1 (919) 234-1277

📢 ProteoGenix Loyalty Program is live — Earn points on every online order. Discover the program

🚀 Special Offer🚀Get 25% off on your bioreagent online order (except Micelles and Nanodiscs), with the code: PROTEOSHOP25

📢 New ! Accelerate your Antibody Development with Ready-to-use Stable Cell Pools

Explore Now
Brand: ProteoGenix

Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

Clonality:
Monoclonal Antibody
Isotype:
IgG1

$238.00

+ 238 loyalty points
Size
Clear
  • In Stock
  • Wide range of unique reagents
  • Fast worldwide delivery
Cilgavimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade

Cilgavimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade

Product name Cilgavimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade
Source DrugBank DB16393
Species Humanized
Molecular weight 150kDa
Purity >85%
Buffer PBS pH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition 4°C for short term; -20°C for long term
Brand ProteoGenix
Applications ELISA,WB
Aliases /Synonyms Cilgavimab,Cilgavimab, AZD1061,Covid Spike RBD,anti-Covid Spike RBD
Reference PX-TA1033
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype IgG1
Clonality Monoclonal Antibody
Product name Cilgavimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade
Source DrugBank DB16393
Species Humanized
Molecular weight 150kDa
Purity >85%
Buffer PBS pH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition 4°C for short term; -20°C for long term
Brand ProteoGenix
Applications ELISA,WB,,,
Aliases /Synonyms Cilgavimab,Cilgavimab, AZD1061,Covid Spike RBD,anti-Covid Spike RBD
Reference PX-TA1033
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype IgG1
Clonality Monoclonal Antibody

Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

Cilgavimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Cilgavimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with Tixagevimab.

About the Spike protein

The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.

A biosimilar of research grade

Cilgavimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use

Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.

  • Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
  • Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z
  • Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
  • Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168

There are no reviews yet.

Be the first to review “Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

Recently viewed products

Loading recently viewed products…

Can’t find what you need?

Our catalog doesn’t cover everything — but our team does. Whether you need a custom antibody, a specific protein variant, or a bulk order, our scientists are here to help.

Contact Our Team Book a Call

Cart (0 Items)

Your cart is currently empty.

View Products